New frontiers in glaucoma treatment: Advances in medical therapy and drug delivery

Glaucoma remains a leading cause of irreversible vision loss worldwide, with intraocular pressure (IOP) being the only modifiable risk factor. While traditional treatments focus on topical medications and surgery, recent advancements in medical therapy and drug delivery systems are reshaping glaucoma management.

The introduction of Rho kinase inhibitors, such as ripasudil and netarsudil, has provided an innovative mechanism for reducing IOP by enhancing aqueous outflow. These medications work by relaxing the trabecular meshwork, though common side effects like conjunctival hyperemia may affect patient adherence. Another major breakthrough is Latanoprostene Bunod (LBN), a nitric oxide-donating prostaglandin analogue that improves both trabecular and uveoscleral outflow, showing superior IOP reduction compared to traditional prostaglandins.

To address issues of medication adherence, sustained-release drug delivery systems are being explored. The bimatoprost intracameral implant (Durysta™) offers long-term IOP control with a single administration, reducing the burden of daily eye drops. Similarly, investigational approaches like travoprost punctal plugs and bimatoprost ocular rings aim to provide continuous drug release with minimal patient intervention. Advances in nanotechnology also hold promise for more targeted and sustained drug delivery.

Beyond pressure control, neuroprotection is a growing area of research, with agents like brimonidine and memantine being evaluated for their role in preserving retinal ganglion cells. Gene therapy and stem cell-based approaches are in early stages but offer hope for regenerative treatments in glaucoma.

As research progresses, these advancements have the potential to revolutionize glaucoma care, improving both efficacy and patient adherence while exploring new therapeutic pathways. Future studies will be crucial in refining these innovations and integrating them into mainstream clinical practice.